Bayer
Bayer Announces 3,200 Job Cuts, Highlights Progress in Pharmaceutical Pipeline
Bayer, job cuts, pharmaceutical pipeline, cost savings, organizational restructuring
Bayer’s Kerendia Achieves Primary Endpoint in Phase III Heart Failure Study
Bayer, Kerendia, finerenone, heart failure, cardiovascular outcomes, Phase III study, FINEARTS-HF
Bayer’s NUBEQA Shows Promise in Prostate Cancer Treatment, Expanding Indications
NUBEQA, darolutamide, prostate cancer, metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, ARASENS trial, ARAMIS trial, Bayer, Orion Corporation
Bayer’s New Drug Shows Promising Phase III Results for Menopause Symptom Relief
Bayer, Phase III results, menopause symptoms, drug, clinical trial, hot flashes, night sweats, hormone therapy
Bayer Initiates Global Workforce Reduction to Streamline Operations
Bayer, workforce reduction, staff cuts, bureaucracy reduction, streamlining operations, global campaign.
Bayer Prepares Menopause Drug Rival to Astellas’ Veozah for Regulatory Filings Following Successful Phase 3 Trials
Bayer, Menopause Drug, Elinzanetant, Phase 3 Hat Trick, Regulatory Approval, Competition with Astellas’ Veozah
Bayer’s Menopause Drug Elinzanetant Achieves Successful Long-Term Results in Phase III Trial, Rivalling Astellas’ Veozah
Bayer, Elinzanetant, Menopause drug, Phase III trial, Long-term results, Hot flashes, Vasomotor symptoms, Astellas, Veozah, Competition
Boundless Bio, Oncology Startup Targeting Extrachromosomal DNA, Files for $100 Million IPO
Boundless Bio, Oncology Startup, Initial Public Offering (IPO), Extrachromosomal DNA (ecDNA), Small Molecule Drugs (ecDTx), Checkpoint Kinase 1 Inhibitors, Phase 1 Trials, Nasdaq Listing (Symbol: BOLD), Backed by Bayer and Arch Venture Partners, Preliminary Data Expected in Second Half of 2024
Bayer Acquires European Rights to BridgeBio’s Acoramidis for ATTR-CM Therapy
Bayer, BridgeBio Pharma, Acoramidis, ATTR-CM, Exclusive License, European Rights, Royalties, Milestone Payments, Phase 3 Data, Potential Approval, Low-Thirties Percent Royalties, EMA Approval 2025, PDUFA Action Date November 2024, Vyndaqel Rival, Blockbuster Potential, Cardiovascular Infrastructure, Investor Hopes for Clarity on Split Strategy.
Bayer Implements 95% Dividend Cut to Reduce Debt Amid CEO Bill Anderson’s Turnaround Plan
Bayer, Euro currency, Reduced, 95%